$TXMD

TherapeuticsMD reported Q2 2026 license revenue of $864,000, down 8.7% year over year, in its Aug. 11 8-K. The company said it has exited research, development, and commercial operations, leaving a royalty stream primarily under the Mayne License Agreement. Net income from continuing operations fell to $164,000, down from $545,000.

TherapeuticsMD, Inc. (TXMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0000025743 0000025743 2026-08-11 2026-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPOR

TherapeuticsMD Inc. (TXMD) stock fell 1.49% on Thursday, closing at $1.99, despite an overall positive trading session for the broader market indices, including the NASDAQ Composite and the Dow Jones Industrial Average. The company's shares are currently 32.54% below their 52-week high of $2.95, which was reached on January 27th.

TherapeuticsMD (NASDAQ: TXMD) reported its first-quarter 2026 financial results, showing a net income from continuing operations of $103 thousand, a notable improvement from a loss in the previous year. The company saw an increase in license revenue, primarily from the Mayne License Agreement, and a decrease in total operating expenses. TherapeuticsMD continues to explore strategic alternatives, including potential acquisitions, mergers, or asset sales, as it transitions its business model to focus on pharmaceutical royalties.

TherapeuticsMD, Inc. (TXMD) has released its Quarterly Earnings Report (Form 10-Q) for the period ending March 31, 2026. The company, which transformed into a pharmaceutical royalty company in December 2022, reported a net income of $95 thousand for Q1 2026, a significant improvement from a net loss of $653 thousand in Q1 2025. This positive shift is primarily due to increased license revenue and reduced operating expenses, even as the company faces ongoing legal disputes and a "going concern" warning due to future liquidity needs.

TherapeuticsMD (TXMD) reported a narrowed net loss from continuing operations to $(0.7) million for 2025, while license revenue significantly increased by 71.6% to $3.0 million. The company is actively evaluating strategic alternatives but faces risks related to licensee performance, regulatory changes, and ongoing disputes. This financial improvement comes as TXMD explores its long-term strategic direction.

TherapeuticsMD (NASDAQ: TXMD) reported its full-year 2025 financial results, showing a net loss of $(0.7) million and license revenues of $3.0 million, an increase of 71.6% from 2024. The company, which transitioned to a pharmaceutical royalty business in December 2022, is actively evaluating strategic alternatives including mergers, acquisitions, or asset sales. TherapeuticsMD emphasizes risks associated with licensee performance, ongoing disputes, and its ability to maintain its Nasdaq listing.

TherapeuticsMD (TXMD) transitioned to a royalty-only model in 2025, reporting $3.0M in license revenue but also a net loss of $569K. The company faces significant going concern doubts due to ongoing litigation with Mayne Pharma and its reliance on royalty income. Future sustainability hinges on securing additional financing and growing its royalty streams.

TherapeuticsMD ( NASDAQ:TXMD ) , a specialty pharmaceutical company focused on women's health products, released its second quarter results on August 12, 2025, reporting a swing to profitability, with GAAP net income from continuing operations of $545 thousand and higher license revenue from ...